Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June…
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1…